Login
$CYRX
$19.80 -$0.09 (0.45%) Live

$CYRX 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Third quarter revenue grew 14% year-over-year to $50.2 million

06 Aug 2026 8-K: Results of Operations and Financial Condition

Second quarter revenue grew 8% year-over-year to $49.0 million

09 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

(as amended by the First Amendment (effective February 25, 2021), the Second Amendment (effective April 30, 2021), the Third Amendment (effective May 17, 2024), and the Fourth Amendment (effective June 5, 2026))

04 May 2026 8-K: Results of Operations and Financial Condition

First quarter revenue grew 16% year-over-year to $47.8 million

03 Mar 2026 8-K: Results of Operations and Financial Condition

FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance

04 Nov 2025 8-K: Results of Operations and Financial Condition

Third quarter revenue increased 15% year-over-year to $44.2 million

06 Aug 2025 8-K: Results of Operations and Financial Condition

Second quarter revenue increased 14% year-over-year to $45.5 million

13 Jun 2025 8-K: Completion of Acquisition or Disposition of Assets; Regulation FD Disclosure

On June 11, 2025, the Company completed the previously disclosed divestiture of its CRYOPDP Business to designated affiliates of DHL Supply Chain International Holding B.V. (“DHL”) for $133.0 million. Pursuant to the terms of the Agreeme...

10 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 6, 2025, Cryoport, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). The final voting results for the proposals submitted to a vote of stockholders at the Annual Meeting, each of which is d...

07 May 2025 8-K: Results of Operations and Financial Condition

Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year

31 Mar 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Cryoport Inc, a corporation incorporated under the laws of the State of Nevada (United States of America) having its registered office at 112 Westwood Place – Suite 350, Brentwood Tennessee 37027,

04 Mar 2025 8-K: Results of Operations and Financial Condition

FY 2024 revenue of $228.4 million, in-line with company guidance

07 Nov 2024 8-K: Results of Operations and Financial Condition

Q3 2024 Life Sciences Services revenue up 9% year-over-year, including BioStorage/BioServices revenue up 12% year-over-year

06 Aug 2024 8-K: Results of Operations and Financial Condition

Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially

06 Aug 2024 8-K: Other Events

$200 million repurchase program authorized to repurchase common stock and/or convertible notes

22 May 2024 8-K: Submission of Matters to a Vote of Security Holders

1.1 Establishment; Impact on Prior Plans. Cryoport, Inc. (the “Company”) hereby establishes the “Cryoport, Inc. 2018 Omnibus Equity Incentive Plan” (the “Plan”). The Plan will supersede and replace the Cryoport, Inc. 2015 Omnibus Equity ...

07 May 2024 8-K: Results of Operations and Financial Condition

9% year-over-year increase in Commercial Cell & Gene Therapy revenue

12 Mar 2024 8-K: Results of Operations and Financial Condition

Year-over-year, Commercial Cell & Gene Therapy revenue rose 33%; BioStorage/BioServices revenue increased 45%

15 Feb 2024 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

This Amended and Restated Employment Agreement (the “Agreement”) is made and entered into effective as of February 15, 2024 (the “Effective Date”) by and between Cryoport, Inc., a Nevada corporation (the “Company”), and Mark Sawicki (“Ex...

15 Nov 2023 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

(a) An annual meeting of the stockholders, for the purpose of the election of directors to succeed those whose terms may expire in such year and for the transaction of such other business as may properly come before the meeting, shall be...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support